Amgen To Challenge Inclusion Of Oral ESRD Drugs With No I.V. Equivalent In Medicare Payment Bundle
This article was originally published in The Pink Sheet Daily
All ESRD drugs, including those currently covered under Medicare Part D, would be paid for under the new proposed bundled payment for end stage renal disease drugs and services in Part B.
You may also be interested in...
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.